The deal includes an upfront payment to Biocytogen, along with eligibility for milestone payments tied to specified ...

Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. ("Qilu Pharmaceutical") for a fully ...

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment hereHOUSTON ...

Tokyo, Japan and Cambridge, UK, 3 September 2026 - Nxera Pharma Co., Ltd. ('Nxera” or 'the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited ('Centessa”), a wholly-owned ...

On July 28, 2023, the United States Food and Drug Administration (FDA) approved ReVive, an opioid reversal medication manufactured by Harm Reduction Therapeutics, a nonprofit pharmaceutical company.

Following the Council of the European Union and the European Parliament reaching an agreement in the trilogue negotiations on the so-called Pharma Package in December 2025, the texts of the ...

LGM Pharma’s Expanded Contract Development and Manufacturing Organization (CDMO) Capabilities Will Enable Customers to Accelerate and Optimize the New Product Pathway from Early Development Through ...

At the end of October, Novartis and Monte Rosa Therapeutics signed a deal to license the start-up’s VAV1 degrader MRT-6160 for possible use in immune conditions. The deal is just one in a series of ...

Donna Conroy, MS is Founder/CEO of SciMar ONE, Inc. a technology company building AI-based SaaS solutions for the pharmaceutical industry. Investing time and resources is clearly a long-term strategy ...

LONDON--(BUSINESS WIRE)--The increasing competition of the pharmaceutical industry has encouraged companies to invest in innovation and drug development. However, the drug development process is ...

Biocytogen inks non-exclusive licensing pact with Qilu Pharmaceutical for a fully human VHH antibody to support innovative drug development in neuroscience: Beijing, China Friday, ...